MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.2008.16.4442

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008

Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy.

Bunin Nancy J, Davies Stella M, Aplenc Richard, Camitta Bruce M, DeSantes Kenneth B, Goyal Rakesh K, Kapoor Neena, Kernan Nancy A, Rosenthal Joseph, Smith Franklin O, Eapen Mary

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАПоддержка службы здравоохранения СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Identify prognostic factors that influence outcome after unrelated donor bone marrow transplantation in children with acute myeloid leukemia (AML).

PATIENTS AND

METHODS

Included are 268 patients (age <or= 18 years) with AML in second complete remission (n = 142), relapse (n = 90), or primary induction failure (n = 36) at transplantation. All patients received bone marrow grafts from an unrelated donor and a myeloablative conditioning regimen. Cox regression models were constructed to identify risk factors that influence outcome after transplantation.

RESULTS

In this analysis, the only risk factor that predicted leukemia recurrence and overall and leukemia-free survival was disease status at transplantation. The 5-year probabilities of leukemia-free survival were 45%, 20%, and 12% for patients who underwent transplantation at second complete remission, relapse, and primary induction failure, respectively. As expected, risk of acute but not chronic graft-versus-host disease (GVHD) was lower with T-cell-depleted bone marrow grafts; T-cell-depleted grafts were not associated with higher risks of leukemia recurrence. We observed similar risks of leukemia relapse in patients with and without acute and chronic GVHD.

CONCLUSION

Children who underwent transplantation in remission had a superior outcome compared with children who underwent transplantation during relapse or persistent disease. Nevertheless, 20% of children who underwent transplantation in relapse are long-term survivors, suggesting that unrelated donor bone marrow transplantation is an effective therapy in a significant proportion of children with recurrent or primary refractory AML.

Для цитирования: Bunin Nancy J, Davies Stella M, Aplenc Richard, Camitta Bruce M, DeSantes Kenneth B, Goyal Rakesh K, Kapoor Neena, Kernan Nancy A, Rosenthal Joseph, Smith Franklin O, Eapen Mary. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008. DOI: 10.1200/jco.2008.16.4442.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.